Trillium Therapeutics Expands Trial of Cancer Drug

Trillium Therapeutics said Wednesday it has further expanded its current intravenous dosing trial of TTI-621 following promising early evidence of anti-tumor activity in patients with both myeloid and lymphoid malignancies.

Changes to the trial of TTI-621, the company’s lead program, include an additional cohort of patients with Hodgkin lymphoma treated with a combination of TTI-621 and the PD-1 checkpoint inhibitor nivolumab; two additional cohorts of patients with T- and B-cell acute lymphoblastic leukemia and small cell lung cancer treated with TTI-621 monotherapy; cautious exploration of dose-intensification, building upon the observation of good overall tolerability associated with attenuated thrombocytopenia over successive weekly doses of TTI-621, and increasing the size of cohorts exhibiting early evidence of clinical benefit. “With emerging data linking CD47 blockade with T cell activation, we are excited to pursue the combination of TTI-621 and nivolumab in an attempt to optimally engage both the innate and adaptive arms of the immune system to generate a robust and enduring anti-tumor response,” said Chief Medical Officer Eric Sievers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Comment